PB2004: BCMA-DIRECTED THERAPY FOR MULTIPLE MYELOMA: EFFECTIVENESS OF ONLINE EDUCATION IN IMPROVING KNOWLEDGE AND COMPETENCE IN PRACTICAL APPLICATION

por Harvey-Jones, V., Koekkoek, S., Vandenbroucque, J., Mateos, M.-V.
Publicado 2022

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDO...

por Quach, H., Leleu, X., Mateos, M.-V., Usmani, S. Z., Nooka, A. K., Goldrick, A., Najdi, R., Shu, N., Facon, T.
Publicado 2022

P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.

por De Ramón, C., Rojas, E. A., Cardona-Benavides, I. J., Mateos, M. V., Corchete, L. A., Gutiérrez, N. C.
Publicado 2022

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Mateos, M. V., Bahlis, N., Costa, L., Perrot, A., Pei, L., Rubin, M., Lantz, K., Sun, W., Jaffe, M., Kobos, R., Nooka, A.
Publicado 2022

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C
Publicado 2018

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., Anderson, K. C.
Publicado 2019

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

por Hari, P, Mateos, M-V, Abonour, R, Knop, S, Bensinger, W, Ludwig, H, Song, K, Hajek, R, Moreau, P, Siegel, D S, Feng, S, Obreja, M, Aggarwal, S K, Iskander, K, Goldschmidt, H
Publicado 2017

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN D...

por Weisel, K., Chari, A., Usmani, S. Z., Goldschmidt, H., Mateos, M.-V., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Slavcev, M., Moreau, P.
Publicado 2022

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE L...

por Einsele, H., Moreau, P., Delforge, M., van de Donk, N. W., Ghilotti, F., Diels, J., Elsada, A., Strulev, V., Pei, L., Kobos, R., Smit, J., Slavcev, M., Weisel, K., Mateos, M.-V.
Publicado 2022

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

por Broijl, A., van de Donk, N., Bosch, F., Mateos, M. V., Rodriguez-Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., van der Vliet, H., Kater, A.
Publicado 2022

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

por Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S
Publicado 2014

P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAP...

por Spencer, A., Moreau, P., Mateos, M.-V., Goldschmidt, H., Suzuki, K., Levin, M.-D., Sonneveld, P., Yoon, S.-S., Usmani, S. Z., Weisel, K., Reece, D., Ahmadi, T., Pei, H., Garvin Mayo, W., Gai, X., Carey, J., Carson, R., Dimopoulos, M. A.
Publicado 2022

P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA

por Diaz-Tejedor, A., San-Segundo, L., Corchete, L. A., González-Méndez, L., Martín-Sánchez, M., Lorenzo-Mohamed, M., González-Rodríguez, M., Cruz-Hernández, M., Sánchez-Blázquez, M., Gutiérrez, N. C., Mateos, M.-V., Garayoa, M., Ocio, E. M., Paíno, T.
Publicado 2022

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPO...

por Weisel, K., Mateos, M.-V., Vincent, L., Martin, T., Berdeja, J. G., Jakubowiak, A., Jagannath, S., Lin, Y., Thilakarathne, P., Ghilotti, F., Diels, J., Haefliger, B., Hague, C., Gonzalez, A., Schecter, J. M., Gries, K. S., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H., Moreau, P.
Publicado 2022

P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Delforge, M., Moreau, P., Einsele, H., De Stefano, V., Lindsey-Hill, J., Vincent, L., Mangiacavalli, S., Perrot, A., Ocio, E., ten Seldam, S., ’. Groen-Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Gries, K. S., Nesheiwat, T., Wapenaar, R., Mateos, M.-V., Weisel, K.
Publicado 2022

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC...

por Martínez-López, J., Moreau, P., Usmani, S. Z., Garfall, A., van de Donk, N. W., San-Miguel, J. F., Oriol, A., Chari, A., Karlin, L., Mateos, M.-V., Popat, R., Nooka, A. K., Sidana, S., Trancucci, D., Verona, R., Girgis, S., Uhlar, C., Stephenson, T., Banerjee, A., Krishnan, A.
Publicado 2022

P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY

por Einsele, H., Moreau, P., De Stefano, V., Dytfeld, D., Angelucci, E., Benjamin, R., Goldschmidt, H., van de Donk, N. W., Besemer, B., Scheid, C., Vij, R., ’. Groen-Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Nesheiwat, T., Wapenaar, R., Weisel, K., Mateos, M.-V.
Publicado 2022

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

por Popat, R., Moreau, P., Usmani, S. Z., Garfall, A., Mateos, M.-V., San-Miguel, J. F., Oriol, A., Nooka, A. K., Rosinol, L., Chari, A., Karlin, L., Krishnan, A., Bahlis, N., Martin, T., Besemer, B., Martínez-López, J., Delforge, M., Fastenau, J., Gries, K. S., van de Donk, N. W.
Publicado 2022

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

por Gay, F, Berdeja, JG, De Stefano, V, Hari, P, Hooper, B, Haltner, A, Kumar, S, Martin, T, Mateos, M-V, Moreau, P, Rosta, E, Samjoo, IA, Usmani, SZ, Weisel, K, Jackson, CC, Olyslager, Y, Schecter, JM, Vogel, M, Garrett, A, Lee, S, Nesheiwat, T, Pacaud, L, Zhou, C, Valluri, S, Costa, LJ, Lin, Y
Publicado 2022

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (B...

por van de Donk, N., Mateos, M.-V., Cohen, Y.C., Rodriguez-Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San-Miguel, J.
Publicado 2023